Positron Corporation (POSC)

[zenvesting]

Flurpiridaz F-18 is going to make cardiac PET MPI much more accessible to small and medium cardiology practices currently using SPECT for MPI.

Digirad, the largest dedicated cardiac SPECT manufacturer's blog provides the most succinct description of why Fluorpiridaz is going to create a sea change from SPECT to PET for non-invasive cardiac imaging:
https://www.digirad.com/flurpiridaz-change-cardiac-pet-imaging/

When the incumbent provides that rosy of an outlook for the coming disruption, you have to respect their intellectual honesty and the said advantages the new technology will bring!

The trial completion is expected in April 2022:
https://clinicaltrials.gov/ct2/show/NCT03354273

WVU indicates the trial enrollment is closed, so it seems to be on schedule:
https://wvumedicine.org/heart/clinical-research/clinical-trials/